3. Definium Therapeutics Inc. (NASDAQ:DFTX)
Number of Hedge Fund Holders — 72
Number of Billionaire Holders — 20
Definium Therapeutics, Inc. (NASDAQ: DFTX) has strengthened its late-stage psychiatric-drug investment case through successive positive studies of DT120, its investigational lysergide orally disintegrating tablet.
On September 14, the company announced that the Phase 3 Panorama study in generalized anxiety disorder met its primary and all key secondary efficacy endpoints. The 100-microgram treatment group achieved a placebo-adjusted 5.1-point improvement on the Hamilton Anxiety Rating Scale at Week 12, with statistical significance of p<0.0001.
The result followed positive findings from the Voyage anxiety study and the Emerge depression study. Multiple successful studies add evidence across the development program, although each indication still requires its own regulatory assessment.
“With strong positive results across four complementary studies, we have built a compelling body of evidence,” CEO Rob Barrow said.
The September update scheduled a pre-NDA meeting for the fourth quarter of 2026 and anticipated an application filing in the first half of 2027. That shifts attention toward the completeness of the filing package, regulatory discussions, safety review, and potential treatment-delivery requirements.
The balance sheet provides substantial resources. Cash, cash equivalents, and investments totaled approximately $1.1 billion at June 30, with management projecting operations funded into 2030. A public offering generated approximately $805 million in gross proceeds, strengthening finances while expanding the share base.
For investors researching psychedelic medicine stocks, commercial delivery deserves as much attention as efficacy. Treatment administration, monitoring, reimbursement, and healthcare-provider capacity could influence adoption if approval is obtained.
Strong clinical findings improve the development proposition, but commercial readiness requires more than a successful statistical readout.
Ranking rationale: Definium Therapeutics, Inc. (NASDAQ: DFTX) ranks third with 20 billionaire holders. Repeated positive late-stage results and substantial financial resources support inclusion, while regulatory execution and eventual treatment economics remain important uncertainties.
